Pharmacy News

The success marks the second Phase III clinical trial in which Kisqali met overall survival.

The drug has been approved under the governing body’s Priority Review designation.

Breast cancer is the most common cancer in women worldwide, with more than two million new cases diagnosed in 2018.

It has also announced the appointment of the company’s new general manager, Craig Bowen.

The partnership will focus on the analysis of the circulating proteome of advanced pancreatic cancer patients treated with IMM-10.

Johnson also took a moment in his speech to announced that he wants to revisit and potentially reverse the sugar tax.

The figure is an increase of 4% from the 2017 total.

Teva recently halted its Ajovy clinical development.

The CHMP’s recommendation will now be reviewed by the European Commission for marketing authorisation.

The news comes shortly after AZ announced positive results from a late-stage trial of the drug.

IQVIA have been confirmed to host the finals days for the 2019 PharmaTimes Marketer of the Year and also the Sales Awards at their offices in Reading.

The money will go to a new UK ‘digital brain bank’, Europe’s largest brain and tissue bank, based in London.

The sales numbers were boosted by oncology drugs such as Tagrisso, Imfinzi and Lynparza.

The drug is a selective sphingosine-1-phosphate receptor 1 (S1P1) modulator.

Scientists are “re-imagining ultrasound technology to develop a treatment that can liquefy cancer cells in the body using microscopic bubbles”.

The application is for cabotegravir and Edurant (rilpivirine) as the first monthly, injectable treatment for HIV.

Rates have increased by more than a third (35%) for women and by almost three-fifths (55%) for men.

But the organisation says it will “need more details of exactly how this will be achieved".

The FDA initially cited insufficient data and refused to accept the initial submission in August 2017.

Increasing health span has been adopted as a policy objective by the UK Government in the Industrial Strategy’s “Ageing Society”.